SCHEMBL3145220

SCHEMBL3145220

CCCCCCCc1ccc(C(=O)CCC(=O)O)cc1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.76
THRA P10827 9/20 0.72
THRB P10828 9/20 0.72
HAO1 Q9UJM8 1/20 0.66
S1PR2 O95136 1/20 0.62
S1PR1 P21453 1/20 0.62
S1PR3 Q99500 1/20 0.62
RARB P10826 5/20 0.62
ALDH1A1 P00352 2/20 0.62
MEN1 O00255 1/20 0.62
RARA P10276 1/20 0.62
MAPT P10636 1/20 0.62
MTOR P42345 1/20 0.62
KMT2A Q03164 1/20 0.62
MMP2 P08253 1/20 0.59
MMP12 P39900 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3130654 1.00 L3MBTL1 (0.76) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL9815969 1.00 L3MBTL1 (0.76) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL10523939 1.00 L3MBTL1 (0.76) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL9356282 1.00 L3MBTL1 (0.76) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL3145641 1.00 L3MBTL1 (0.76) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL3135443 0.98 L3MBTL1 (0.78) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL8754744 0.94 L3MBTL1 (0.71) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL7813104 0.93 L3MBTL1 (0.81) L3MBTL1THRATHRBHAO1RARB
Butylbenzyl SCHEMBL8119801 0.92 L3MBTL1 (0.69) L3MBTL1THRATHRBHAO1S1PR2
SCHEMBL9075808 0.92 THRA (0.70) L3MBTL1THRATHRBHAO1S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642344-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2010-01-05 US claimed
EP-0992511-B1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES INC (US) 2009-03-11 EP claimed
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2008-01-10 US claimed
US-7247434-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2007-07-24 US claimed
EP-0868535-B9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2007-05-09 EP claimed
EP-0868535-B2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2006-01-04 EP claimed
CN-1515541-A Method for detecting ligand pair combination by using non-fluorescent marker and its composite ռ�˹ 2004-07-28 CN claimed
US-20040115694-A1 Methods and compositions for determining the sequence of nucleic acid molecules QIAGEN GENOMICS, INC. 2004-06-17 US claimed
EP-0990047-B1 METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY QIAGEN GENOMICS INC (US) 2003-05-14 EP claimed
US-20030077595-A1 Methods and compositions for enhancing sensitivity in the analysis of biological-based assays QIAGEN GENOMICS, INC. 2003-04-24 US claimed
US-6027890-A DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY RAPIGENE, INC. (US) 2000-02-22 US claimed
EP-0962464-A2 Methods and compositions for detecting binding of ligand pair using non-fluorescent label Rapigene, Inc. (US) 1999-12-08 EP claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
CN-1212019-A Methods and compositions for detecting ligand pair binding using non-fluorescent labels RAPIGENE INC (US) 1999-03-24 CN claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules CPSF6, RNMT, POLM L3MBTL1 203/4885THRA 3021/4885THRB 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.